A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IITreatmentActive18 and overOther12-005
ACS IRG 58-012-49, NCT00730158

Trial Description


KD018 is an oral form of a spray dried aqueous extract composed of four main herbs, which have been used in the Orient for nearly 2000 years for a variety of GI symptoms including diarrhea and nausea/vomiting. Extensive pre-clinical research has been done with Chinese herbal medicine, and studies have documented significant anticancer activity in combination with various cytotoxic agents including Irinotecan, which is a semi-synthetic derivative of the natural alkaloid camptothecin and belongs to the class of topoisomerase I inhibitors. The proposed plan will investigate the mechanism and efficacy of Chinese herbal medicine as an adjunct to chemotherapy in treatment of patients with metastatic colorectal cancer. Our rationale for the therapeutic use of KD018 is its potential activity in reducing chemotherapy-induced toxicity, especially diarrhea.

Eligibility Criteria

Inclusion Criteria:

1. Patients with histologically confirmed metastatic colorectal cancer (mCRC), who have received and/or progressed on a prior oxaliplatin-based chemotherapy regimen.

2. Patients must have been off of chemotherapy for at least 4 weeks prior to signing the informed consent/start of screening.

3. Patients with wild-type or mutant KRAS mCRC.

4. At least one measurable lesion by RECIST 1.1.

5. ECOG PS Performance Status 0-2.

6. Must be >/=18 years of age.

7. Expected survival of at least 6 months.

8. Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use acceptable contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive or double barrier device), and must have a negative serum or urine pregnancy test within 1 week prior to beginning treatment on this trial. Nursing patients are excluded. Sexually active men must also use acceptable contraceptive methods. Pregnant and nursing patients are excluded because the effects of the combination of KD018 and irinotecan on a fetus or nursing child are unknown.

9. Must be able and willing to give written informed consent.

10. Patients must have the following clinical laboratory values:

1. ANC count >/= 1,500/ mm3.

2. Platelets >/= 100,000/ mm3.

3. Hemoglobin >/= 9 gm/dL (may be corrected by transfusion).

11. Evidence of adequate hepatic function, Bilirubin < 1.5 x upper limit of normal (ULN) AST </= 2.5 x ULN or ALT </= 2.5 x ULN (Note, if both AST and ALT are done, both must be </= 2.5 x ULN) OR AST </= 5.0 x ULN or ALT </= 5.0 x ULN is acceptable if liver has tumor involvement. (Note, if both AST and ALT are done, both must be </= 5.0 x ULN)

12. Serum creatinine </=2 x ULN

13. Serum potassium within institutional limits of normal (may be corrected with potassium repletion).

Exclusion Criteria:

1. Continued treatment with bevacizumab with documented evidence of disease progression on a bevacizumab-containing regimen.

2. Uncontrolled or symptomatic brain metastasis.

3. Serious concomitant systemic disorders (e.g., active infection) that, in the opinion of the investigator, would compromise the safety of the patient or compromise the patient's ability to complete the study.

4. Unwilling or unable to follow protocol requirements or to give informed consent.

5. No treatment with cytotoxic or biologic agents within the 4 weeks prior to beginning treatment on this study (6 weeks for mitomycin or nitrosoureas). At least 4 weeks must have elapsed from any prior surgery, radiation, hormonal or other drug therapy for their cancer.

6. Known HIV positivity, as safety in this patient population has not been assessed.

7. Presence of metastatic disease that, in the opinion of the investigator, would require palliative treatment within 4 weeks of enrollment.

8. Altered mental status precluding understanding of the informed consent process and/or completion of the necessary studies.

9. Pregnant or breast-feeding women.

10. Men and women of childbearing age and potential, who are not willing to use effective contraception.

11. Major surgery within the previous 4 weeks.

12. Patients taking concurrent medications of any kind which are strong inducers or inhibitors of CYP3A4.

13. Patients previously treated with an irinotecan-containing regimen.

Trial Contact Information

Trial Lead Organizations/Sponsors

UPMC Cancer Centers

  • Kadmon Pharmaceuticals
Edward Chu, MD, Principal Investigator
Rita Johnson
Ph: (412) 647-8571
Email: johnsonr1@upmc.edu

Trial Sites


New Haven

Yale Cancer Center

Howard Hochster, MD
Ph: 203-785-5756
Email: howard.hochster@yale.edu

Howard Hochester, MD
Principal Investigator


Hillman CancerCenters

Edward Chu, MD
Ph: 412-648-6589
Email: chue2@upmc.edu

Edward Chu, MD
Principal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifier NCT00730158
ClinicalTrials.gov processed this data on November 12, 2014

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.